Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer

British Journal of Cancer

Volumn 76, Issue 3, 1997, Pages 306-311

  Schmitt, M ^a   Thomssen, C ^a   Ulm, K ^a   Seiderer, A ^a   Harbeck, N ^a   Hofler H ^a   Janicke F ^a   Graeff, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; PAI 1; Prognosis; Protease; Steroid hormone receptor; Time variation; Urokinase; Urokinase type plasminogen activator

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; STEROID RECEPTOR; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIOASSAY; STATISTICAL ANALYSIS;

EID: 0030838482     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.383     Document Type: Article

References (39)

1. Altman DG, Lausen B, Sauerbrei W and Schumacher M (1944) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
2. Barbareschi M, Gasparini G, Morelli L, Forti S and Della-Palma P (1995) Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 36: 181-192
3. Breiman L, Friedman JH and Olsen RA (1984) Classification and Regression Trees. Wadsworth: Belmont
4. Brünner N, Pyke C, Hansen CH, Romer J, Grøndahl-Hansen J and Danø K (1994) Urokinase plasminogen activator (uPA) and its type I inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 71: 299-309
5. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-200
6. Duffy M, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988). Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62: 531-533
7. Duffy MJ, Reilley D, O'Sullivan C, O'Higgins N, Fennelly JN and Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
8. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ and Duffy MJ (1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
9. Estreicher A, Muhlhauser J, Carpentier JL, Orci L and Vassalli JD (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792
10. 1 integrins on fibroblasts. Nature 383: 438-440
11. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Jänicke F and Klijn JMG (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
12. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
13. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB and Verspaget HW (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071
14. Gray RJ (1992). Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87: 942-951
15. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
16. Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S and Ishikawa E (1989) Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res 49: 1067-1070
17. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW and Schildberg FW (1995) Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Med 1: 1035-1039
18. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U and Schildberg FW (1995) Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase type plasminogen activator system. J Clin Oncol 13: 2084-2093
19. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M and Grothe F (1996) Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 155: 858-862
20. Holmgren L, O'Reilly MS and Folkman J (1995) Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 2: 149-153
21. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen Ch, Prechtl A and Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type I. Cancer Res 54: 2527-2530
22. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and of their inhibitor PAI-1 in breast cancer. Semin Thromb Hemostas 17: 303-312
23. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
24. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
25. Kanse S, Kost C, Wilhelm O, Andreasen PA and Preissner KT (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344-353
26. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
27. Kobayashi H, Fujishiro S and Terao T (1994) Impact of urokinase type plasminogen activator and its inhibitor type I on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548
28. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F and Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409
29. Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Marin S and Syrjanen K (1992) The changing importance of prognostic factors in breast cancer during long-term follow-up. Int J Cancer 51: 698-702
30. Liu G, Shuman MA and Cohen RL (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506
31. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
32. Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K and Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
33. Schmitt M, Jänicke F and Graeff H (1992) Tumor-associated proteases. Fibrinolysis 4 (suppl.): 3-26
34. Sier CM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PH, Verheijen JH, Dooijewaard G, Welvaart K, van de Velde CJ, Lamers CB and Verspaget HW (1994) Inactive urokinase and increased levels of its inhibitor type I in colorectal cancer liver metastasis. Gastroenterology 107: 1449-1456
35. Statistical Sciences (1993) S-PLUS Guide to Statistical and Mathematical Analysis, Version 3.2. StatSci: Seattle, WA
36. 3 binding to vitronectin. Nature 383: 441-443
37. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-15
38. Xing RH and Rabbani SA (1996) Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 67: 423-429
39. Yoshimoto M, Sakamoto G and Ohashi Y (1993) Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 10: 2993-3001